Site Search Equity Story Investor Relations At a glance Equity Story Global leader in Sample to Insight solutions QIAGEN serves more than 500,000 customers with differentiated molecular solutions to enable research and the growing applications of clinical testing. Our instruments, consumables and software technologies span seamless workflows to take customers from start to finish – preparing samples, analysing and interpreting variations, and reporting actionable findings. We are leveraging state-of-the-art technologies in our 5 Pillars of Growth (see our Strategy page for more details on these portfolios) to capture mid-term growth in dynamic markets. Leading positions in attractive markets QIAGEN has deep relationships in two major customer classes which are experiencing robust market growth: Molecular Diagnostics: Healthcare providers transforming medicine with molecular insights for prevention, diagnosis and monitoring of diseases Life Sciences: Pharmaceutical and biotechnology companies using genomic insights to guide the discovery and development of innovative new treatments Scientists in academia unlocking the mysteries of life such as mechanisms, pathways and potential treatments of diseases, as well as environmental and biological questions Government or industry laboratories meeting needs in forensics, veterinary diagnostics and food safety Strong financial position and cash flow generation QIAGEN’s strong balance sheet, healthy free cash flow and disciplined capital allocation enable us to invest in organic growth and targeted M&A while improving returns to shareholders. In accelerating QIAGEN’s growth trajectory, we are also managing the business to deliver operating leverage and enhance profitability and shareholder value. Wide global sales reach Geographically, QIAGEN has robust product portfolios and sales efforts in over 85 countries including major markets of the North America, Europe and Asia-Pacific regions. Additionally, we have distribution partners in over 60 countries and continue to expand in emerging markets. Committed to sustainable and responsible business practices We are dedicated to sustainability in our operations and committed to cultivation of a highly talented diverse global workforce and strong governance at the executive and board level. IR Contacts John Gilardi Vice President Head of Corporate Communications and Investor Relations Germany +49 2103 29 11711 U.S. +1 240 686 2222 The Netherlands +31 773 55 66 66 john.gilardi@qiagen.com Download VCARD Phoebe Loh Senior Director Investor Relations +49 2103 29 11457 phoebe.loh@qiagen.com Download VCARD Alexandra Koenig Investor Relations Coordinator +49 2103 29 11709 alexandra.koenig@qiagen.com Download VCARD Email Alerts Email Address SIGN UP Press Releases Events Presentations SEC-Filings End of Day Stock Quote Unsubscribe Follow Us linkedin open in new window facebook open in new window twitter open in new window youtube open in new window linkedin open in new window Contact Us call back mail BACK TO TOP This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Sample to Insight © QIAGEN 2013-21. All rights reserved Privacy Policy Trademarks & Disclaimers Accessibility Powered By Q4 Inc. 5.56.0.1 (opens in new window)